BioMérieux debuts unrated at tight spread
BioMérieux, the French medical diagnostics company, sold its first bond on Monday to a warm reception that showed just how tightly unrated companies can price.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts